@article{Ray:2018:10.1111/bju.14249,
author = {Ray, AF and Powell, J and Speakman, MJ and Longford, NT and DasGupta, R and Bryant, T and Modi, S and Dyer, J and Harris, M and Carolan-Rees, G and Hacking, N},
doi = {10.1111/bju.14249},
journal = {BJU INTERNATIONAL},
pages = {270--282},
title = {Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study)},
url = {http://dx.doi.org/10.1111/bju.14249},
volume = {122},
year = {2018}
}

Download

TY  - JOUR
AB  - ObjectivesTo assess the efficacy and safety of prostate artery embolization (PAE) for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and to conduct an indirect comparison of PAE with transurethral resection of the prostate (TURP).Patients and MethodsAs a joint initiative between the British Society of Interventional Radiologists, the British Association of Urological Surgeons and the National Institute for Health and Care Excellence, we conducted the UK Register of Prostate Embolization (UKROPE) study, which recruited 305 patients across 17 UK urological/interventional radiology centres, 216 of whom underwent PAE and 89 of whom underwent TURP. The primary outcomes were International Prostate Symptom Score (IPSS) improvement in the PAE group at 12 months postprocedure, and complication data postPAE. We also aimed to compare IPSS score improvements between the PAE and TURP groups, using noninferiority analysis on propensityscorematched patient pairs. The clinical results and urological measurements were performed at clinical sites. IPSS and other questionnairebased results were mailed by patients directly to the trial unit managing the study. All data were uploaded centrally to the UKROPE study database.ResultsThe results showed that PAE was clinically effective, producing a median 10point IPSS improvement from baseline at 12 months postprocedure. PAE did not appear to be as effective as TURP, which produced a median 15point IPSS score improvement at 12 months postprocedure. These findings are further supported by the propensity score analysis, in which we formed 65 closely matched pairs of patients who underwent PAE and patients who underwent TURP. In terms of IPSS and qualityoflife (QoL) improvement, there was no evidence of PAE being noninferior to TURP. Patients in the PAE group had a statistically significant improvement in maximum urinary flow rate and prostate volume reduction at 12 months postprocedure. PAE
AU  - Ray,AF
AU  - Powell,J
AU  - Speakman,MJ
AU  - Longford,NT
AU  - DasGupta,R
AU  - Bryant,T
AU  - Modi,S
AU  - Dyer,J
AU  - Harris,M
AU  - Carolan-Rees,G
AU  - Hacking,N
DO  - 10.1111/bju.14249
EP  - 282
PY  - 2018///
SN  - 1464-4096
SP  - 270
TI  - Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study)
T2  - BJU INTERNATIONAL
UR  - http://dx.doi.org/10.1111/bju.14249
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440903800019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/63055
VL  - 122
ER  - 

Download